Measuring Fibrosis: Is Seeing Really Believing?

Nguyen, Thao Thi Thu; Sterling, Richard K.

doi:10.1007/s10620-012-2278-1

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-invasive morphological imaging is provided by various ultrasound (US) technologies, magnetic resonance imaging (MRI), and computed tomography (CT) [2,[12][13][14]. These technologies are widespread in clinical routine and provide high-resolution images of internal organ features, usually without the need for contrast agents.…”

Section: Introduction 1fibrosis In Health and Diseasementioning

confidence: 99%

Radiotracers for Imaging of Fibrosis: Advances during the Last Two Decades and Future Directions

Eriksson,

Velikyan

2023

Pharmaceuticals

View full text Add to dashboard Cite

Fibrosis accompanies various pathologies, and there is thus an unmet medical need for non-invasive, sensitive, and quantitative methods for the assessment of fibrotic processes. Currently, needle biopsy with subsequent histological analysis is routinely used for the diagnosis along with morphological imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). However, none of these imaging techniques are sufficiently sensitive and accurate to detect minor changes in fibrosis. More importantly, they do not provide information on fibrotic activity on the molecular level, which is critical for fundamental understanding of the underlying biology and disease course. Molecular imaging technology using positron emission tomography (PET) offers the possibility of imaging not only physiological real-time activity, but also high-sensitivity and accurate quantification. This diagnostic tool is well established in oncology and has exhibited exponential development during the last two decades. However, PET diagnostics has only recently been widely applied in the area of fibrosis. This review presents the progress of development of radiopharmaceuticals for non-invasive detection of fibrotic processes, including the fibrotic scar itself, the deposition of new fibrotic components (fibrogenesis), or the degradation of existing fibrosis (fibrolysis).

show abstract

Section: Introduction 1fibrosis In Health and Diseasementioning

confidence: 99%